That's why I knew it would bounce. They actually make money. Hey... Our Swede from the conference call lol: CEO Gersh. “People put us in the same category as the highfliers who have revenue growth, but no profitability and no cash generation,” said Gersh. “We have a tremendous war chest.” A war chest Stoney!!! Does GBA have a war chest? We need a war chest Stoney! Bring it up at the next board meeting. Are there any Swedish track stars we can nominate for the board?
I have to go to the damn gym I'm going for it but be careful!! GUMMY GUMMY-> PRAY FOR STONEY CI&T Inc. (CINT) In at $12.95 12.95-0.77 (-5.61%) As of 10:06AM EDT.
From the watchlist "T" PSTG is $24.50>>>>> Hmmmmm What say you Stoney? That's been a pretty stalwart stock. Edit: I like PSTG better I think.
IRA order: Buy 500 CSCO @ $39.89 Might adjust it down if it just creeps lower. Hoping to catch a spike though.
Cramer said he's "extremely bullish" on energy. God bless him. If history is any metric, he may have just saved our economy. Next stop>>> WTI @ $65
Mid Day Gummy Buy MRSN $3.46<---------- Bain Capital's Andrew Hack buys shares worth ~$1.1M in Mersana Therapeutics May 19, 2022 2:11 PM ETMersana Therapeutics, Inc. (MRSN)By: Anuron Mitra, SA News Editor Mersana Therapeutics (NASDAQ:MRSN) said Bain Capital Life Sciences managing director Andrew Hack this week bought 350K shares of the company at $2.91-$3.41, worth ~$1.1M. The clinical stage biotech disclosed the share purchases in a form 4 SEC filing from Wednesday. Bain Capital Life Sciences is the investment arm of Bain Capital that invests in pharmaceutical, biotechnology, medical device, diagnostic and life science tool companies. Andrew Hack joined Bain Capital in 2019 as managing director of Bain Capital Life Sciences. Before that, he was CFO at Editas Medicine (EDIT) from 2015 to 2019. Separately, MRSN on Thursday said the U.S. FDA had given an orphan drug designation to the company's gastric cancer treatment candidate XMT-2056. MRSN stock +5.8% to $3.48 in afternoon trading.